

AGENDA

Pediatric Oncology Experimental Therapeutics Investigator's Consortium

POETIC Winter Meeting 2021 – Virtual Meeting

February 18th and 19th, 2021



Thursday, February 18th, 2021

Thursday Feb 18th MORNING SESSION 8:00 AM 11:30 AM (PT)

CONNECTIVITY (TEST SYSTEM) AND MEETING OPENING AND INTRODUCTIONS

8:00 – 8:15 AM (PT)

Norman Lacayo, MD
Director, POETIC

THE RACE FOR CHILDREN ACT: CHANGING THE LANDSCAPE FOR PEDIATRIC CANCER DRUG DEVELOPMENT

8:15 – 9:00 AM (PT)

Keynote speaker **Gregory Reaman, MD**
Associate Director, Office of Hematology and Oncology Products, CEDER, U.S. FDA

DRUG DEVELOPMENT: A EUROPEAN PERSPECTIVE

9:00 - 9:45 AM (PT)

Michel Zwaan, MD
Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands

THE DRUG REDISCOVERY PROTOCOL: EXPANDED USE OF EXISTING ANTICANCER DRUGS

9:45-10:30 AM (PT)

Laurien J. Zeverijn, MD
Department of Molecular Oncology and Immunology, Laboratory of Emile Voest
Netherlands Cancer Institute, Amsterdam

60 MIN LUNCH BREAK

10:30-11:30 AM (PT)

Thursday Feb 18th, AFTERNOON SESSION

11:30 AM – 3:00 PM (PDT)

11:30 – 11:45 AM (PT)

GHANA PROJECT

Tanya Trippett, MD

*Co-Founder and Director Emeritus, POETIC
Pediatric Hematologic Malignancies, Memorial Sloan Kettering Cancer Center*

11:45 AM – 12:00 PM (PT)

POETIC UPDATES: POE16-01 STUDY

Tanya Trippett, MD

*Co-Founder and Director Emeritus, POETIC
Pediatric Hematologic Malignancies, Memorial Sloan Kettering Cancer Center*

12:00 – 12:15 PM (PT)

POETIC UPDATES: POE14-01 STUDY

Jessica Boklan, MD

*Director, Clinical Oncology Research; Director, Early Drug Development Program; Co-Director,
Leukemia, Lymphoma, Histiocytosis Program, Phoenix Children's Hospital*

Aru Narendran, MD, PhD, FAAP

Professor of Oncology and Pediatrics, Alberta Children's Hospital

12:15 – 12:45 PM (PT)

GENENTECH PEDIATRIC CLINICAL DEVELOPMENT UPDATE

Ronald Bernardi, MD, PhD

*Associate Medical Director, innovative Pediatric Oncology Drug Development (iPODD), Product
Development Oncology (PDO) Roche/Genentech*

12:45 – 1:15 PM (PT)

PARPAML: A PHASE 1 PROTOCOL FOR RELAPSED PEDIATRIC AML TO DETERMINE THE SAFETY AND EFFICACY OF THE PARP INHIBITOR TALAZOPARIB IN COMBINATION WITH CONVENTIONAL CHEMOTHERAPY

Jennifer Kamens, MD

*Instructor, Stanford University and Lucile Packard Children's Hospital, Pediatrics Hematology
Oncology, Stanford*

1:15 - 1:30 PM (PT)

15 MIN BREAK (+KUDOS CORNER)

1:30 – 2:00 PM (PT)

NOVEL THERAPEUTIC AGENTS FOR NEXT GENERATION POETIC CLINICAL TRIALS

Aru Narendran, MD, PhD, FAAP

Professor of Oncology and Pediatrics, Alberta Children's Hospital

2:00 – 2:30 PM (PT)

EXOSOME BIOMARKERS FOR EARLY CANCER DETECTION IN ADULT AND PEDIATRIC CANCERS

David Lyden, MD, PhD

Professor of Pediatrics and Cell and Developmental Biology, Cornell University

2:30 – 3:00 PM (PT)

EXPANDED ACCESS: WHAT IS IT AND HOW CAN IT HELP PEDIATRIC CANCER PATIENTS AND RESEARCHERS?

Mark Shapiro, MBA, MA

VP Clinical Development, xCures

3:00 – 3:30 PM (PT)

THE ZERO PROGRAM

Glenn Marshall, AM, MB, BS, MD, FRACP, FAHMS

Pediatric Hem-Onc, Kids Cancer Centre, Sydney Children's Hospital, Australia

MEETING ADJOURNED

Friday, February 19th, 2021

Friday February 19th MORNING SESSION

8:00 AM – 11:30 AM (PT)

CONNECTIVITY (TEST SYSTEM) GREETINGS/INTRODUCTIONS

8:00 – 8:10 AM (PT)

Norman Lacayo, MD
Director, POETIC

8:10 – 9:00 AM (PT)

COMPASSIONATE USE FOR PEDIATRIC PATIENTS: ETHICS, REGULATION, AND OVERSIGHT

Alison Bateman-House, MPH, PhD, MA
Assistant Professor, Division of Medical Ethics, NYU Grossman School of Medicine

9:00 – 9:30 AM (PT)

**PATIENT ADVOCATE TALK-
EXPANDED ACCESS OF ONC201 FOR DIFFUSE MIDLINE GLIOMA (DMG)**

Anne Donguy
Patient advocate-Parent

9:30 – 10:00 AM (PT)

SURVIVORSHIP AND SYMPTOM MANAGEMENT

Stephanie Smith
Instructor, Pediatrics Hematology Oncology, Stanford

10:00-11:30 AM (PT)

90 MIN LUNCH BREAK

10:00 – 10:30 AM (PT)

GRAB YOUR LUNCH AND JOIN A WORKING GROUP

10:30 – 11:30 AM (PT)

POETIC WORKING GROUPS BREAKOUT ROOMS (+LUNCH)

Friday February 19th AFTERNOON SESSION

11:30 AM – 3:00 PM (PT)

CLINICAL ACTIVITY AND BIOMARKER ANALYSES OF ODRONEXTAMAB (REGN1979), A HUMAN CD20 x CD3 BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

11:30 AM – 12:00 PM (PT)

Srikanth Ambati, MBBS, MD
Senior Medical Director, Clinical Sciences Oncology and Hematology, Regeneron

12:00 – 12:30 PM (PT)

DEVELOPMENT OF APL-101, A HIGHLY SPECIFIC C-MET INHIBITOR, FOR LUNG AND BRAIN CANCERS

Sanjeev Redkar, PhD, MBA
President, Apollomics

12:30 – 1:00 PM (PT)

JOHNSON AND JOHNSON MENIN PROGRAM AND PEDIATRICS

Nikki Daskalakis, MD
Executive Director, Early Development Oncology, The Janssen Pharmaceutical Companies of J&J

1:00 – 1:15 PM (PT)

15 MIN BREAK

1:15 – 1:45 PM (PT)

BRAIN IMMUNOLOGY AND IMMUNOTHERAPY IN BRAIN TUMORS

David M. Ashley, MBBS (Hon), FRACP, PhD
Director, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University

TRANSFORMING THE WAY RESEARCHERS SHARE DATA – LESSONS FROM THE PEDIATRIC CANCER DATA COMMONS

Samuel Volchenbom, MD, PhD

*Dean of Master's Education
Associate Professor of Pediatrics
Director, Pediatric Cancer Data Commons
Associate Director, Institute for Translational Medicine
Associate Chief Research Informatics Officer*

1:45 – 2:15 PM (PT)

OVERVIEW OF THE BAYER ONCOLOGY PIPELINE: PEDIATRIC EDITION

Flavia Menezes, MD

Senior Clinical Development Leader-Pediatric Oncology, Bayer

John Chung, MD

Pediatric Oncology Development Lead and Early Oncology Lead, Bayer

2:15 – 2:45 PM (PT)

MEETING ADJOURNED

POETIC PI MEETING (Closed Session)

3:30 – 5:00 PM (PT)

3:30-3:50 PM (PT)

Jonathan D. Schwartz, DO MSPH FAAP

*Pediatric Neuro-Oncology
Assistant Professor of Pediatrics
Division of Pediatric Hematology/Oncology
Department of Pediatric and Adolescent Medicine
Mayo Clinic, Rochester*